

## Financial Results - Q1 2013



Chris Parratt, CFO
Steven Vandenbogaerde, Finance Director



### Forward-looking statements







This Presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management's current intentions, beliefs or expectations relating to, among other things, Ontex's future results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. By their nature, forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results or future events to differ materially from those expressed or implied thereby. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.

Forward-looking statements contained in this Presentation regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on any such forward-looking statements, which speak only as of the date of this Presentation.

The information contained in this Presentation is subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein and no reliance should be placed on it.

Most of the tables are shown in € million for transparency reasons. This may give rise to rounding differences.





### Reclassification







A small number of customers have been reclassified to a different division in 2013, in line with the account and sales management. To allow for relevant comparisons, the 2012 sales by division have been restated


A bridge reconciliation is provided below:


In €m	Q1 2012	Q2 2012	Q3 2012	Q4 2012	FY 2012
Healthcare	(0.5)	(0.6)	(0.4)	(0.4)	(1.9)
Retails	0.3	0.4	0.3	0.3	1.3
Turkey	0.2	0.2	0.1	0.1	0.6
Total	-	-	-	-	-











# Overview













# Continued Growth in Sales and Investments in Q1 2013







- Total sales at €340.5 million, a 2.1% increase compared to Q1 2012
  - Sales up 2.7% at constant currency year-on-year
- Adjusted EBITDA at €38.0 million, down 6.2% compared to Q1 2012
  - Favourable impact from additional volume and cost savings initiatives were offset negatively by currency fluctuations and increased raw material costs
  - Further increases in investment in new markets help to drive sales but depress short term profitability
- Free Cash Flow at €14.2 million versus €10.0 million in Q1 2012
  - Working capital consumption of €6.1 million compared to €23.2 million in Q1
     2012
  - Spend on Capex at €16.2 million compared to €7.9 million
- Net Debt at €797.8 million as of March 31, 2013





### **Principle Macro Effects**







#### Sales

- Continued growth in emerging countries
  - In particular baby and incontinence product groups
- Western Europe situation varies by country but generally slightly more positive outlook than Q1 2012

#### **FX and Raw Materials**

- Raw material costs slightly higher than Q4 2012 and Q1 2012 as anticipated
- Adverse currency impact primarily from GBP





### **Key Projects on Track**







### Closure of Recklinghausen largely completed

- Production stopped in March with remaining inventory being sold out
- Severance compensation paid largely in April
- Redeployment of existing equipment to other group sites in progress

### Integration of Serenity underway

- Deal closed on April 4
- All carve-out and operational aspects progressing well, no change to expected synergies
- Trading in line with expectations
- €30.0 million of the RCF has been drawn as of April 2013, pending closing of the Serenity factoring agreements





### Market Dynamics Evolving Post K-C Exit









- Kimberly-Clark UK plant closed in March 2013; Spanish plant expected to close in May
  - K-C stockpiling (primarily of private label products) due to previous delivery commitments expected to unwind from H2 onwards
- Huggies market share becomes available as the brand is withdrawn
  - Retailers driving shelf allocation based on commercial aspirations leading to significantly increased private label volumes in some Western European countries
- Opportunity from Kimberly-Clark's private label market developing more slowly than anticipated
  - A number of private label contracts have been secured
  - In some instances retailers' price expectations are not realistic
  - Stockpiling by K-C is delaying the transfer process











# Financials













### Q1 2013 Financial Highlights (1/2)







In €m	Q1 2013	Q1 2012	%
Revenues	340.5	333.4	2.1%
Revenues at constant currency	342.4	333.4	2.7%
Cost of sales	(253.6)	(251.8)	0.7%
Gross profit	86.9	81.6	6.5%
Opex <sup>1</sup>	(56.5)	(48.6)	16.3%
Adjusted EBITDA <sup>2</sup>	38.0	40.5	(6.2)%
Adjusted EBITDA <sup>2</sup> at constant currency	41.5	40.5	2.5%

#### Opex Increase from Q1 2012 mostly driven by:

- Sales & Marketing
  - Investment in developing markets
  - Unusually low Q1 2012 spend
- Logistics
  - Increase reflects higher volume particularly in export markets and also price increases during 2012
- Currency effects



<sup>2:</sup> For definition and reconciliation of Adjusted EBITDA please see Ontex Financial Report for Q1 2013



<sup>1:</sup> Defined as the sum of distribution expenses, sales and marketing expenses, general and administrative expenses, other operating income but excluding non-recurring expenses

## Q1 2013 Financial Highlights (2/2)







In €m	Q1 2013	Q1 2012	%
Adjusted EBITDA <sup>1</sup>	38.0	40.5	(6.2)%
Non recurring expenses <sup>2</sup>	(2.1)	(2.7)	(22.2)%
Reported EBITDA	35.9	37.8	(5.0)%
Depreciation & Amortization	(7.9)	(7.7)	2.6%
Operating profit	28.0	30.1	(7.0)%





<sup>1:</sup> For definition and reconciliation of Adjusted EBITDA please see Ontex Financial Report for Q1 2013

<sup>2:</sup> Non-recurring expenses excluding amortization

## Q1 2013 Revenues Details







In €m	Q1 2013	Q1 2012 <sup>1</sup>	% as reported	% at constant currency
Per division				
Retail	221.7	226.8	(2.2)%	(1.8)%
Healthcare	67.3	65.6	2.6%	3.2%
Turkey Region	51.5	41.0	25.6%	27.1%
Per product group				
Baby	191.2	188.3	1.5%	2.3%
Femcare	48.2	48.3	(0.2)%	0.0%
Incontinence	97.3	92.1	5.6%	6.0%
Other	3.8	4.7	(19.1)%	(17.8)%
Per geographic area				
Western Europe	218.9	226.7	(3.4)%	(3.0)%
Eastern Europe	47.2	44.1	7.0%	6.9%
Rest of the world	74.4	62.6	18.8%	20.4%

<sup>1:</sup> Sales by division restated in 2013 due to customer reclassification.





# Free Cash Flow Generation Improves as WC Consumption Decreases







In €m	Q1 2013	Q1 2012
Adjusted EBITDA	38.0	40.5
Changes in WC	(6.1)	(23.2)
Cash taxes paid	(1.5)	0.6
Capex	(16.2)	(7.9)
Free Cash Flow	14.2	10.0

- Working capital management in line with plan
  - Inventory levels increased as Recklinghausen production continued through most of Q1 2013
- Capex in line with expectations with higher proportion of investment in the first half of 2013 (different phasing compared with 2012)
- Higher cash taxes
  - Q1 2012 was impacted by a significant refund of German taxes





# Temporary Drawdown of RCF Facility Post Q1 2013







In €m	As of March 31, 2013
Cash & Cash Equivalents	43.0
Credit Lines (of which drawn: €0.0 million)	75.0
Available Liquidity	118.0

In €m	Pro-Forma as of March 31, 2013
Available liquidity	118.0
Bond Issue in Escrow	77.4
Serenity Payment at Closing	(73.2)
Working Capital Ramp Up	(33.8)
Available Liquidity	88.4

- RCF draw down of €30.0 million in April 2013 pending closing of factoring agreement for Serenity
- On-going negotiations on multiple factoring agreements with different parties
- Part of facility confirmed in May






### **Net Debt Bridge**









<sup>\*</sup> Including cash taxes as well as other cash inflow and outflow related to operating and investing activities



### **Outlook / Progressing into 2013**







#### Serenity Update:


- Serenity will be consolidated from April 4 into the Healthcare division for the Q2 results
- Progress to date on trading, integration and synergies has been encouraging
- Raw Material outlook for the next two quarters
  - Raw material environment is stable
  - Q2 2013 raw materials in line with Q1 2013
  - Initial indications for Q3 2013 suggest no material changes from Q2 2013











# Q&A - Q1 2013









